UPDATE 1-Takeda Pharma reports five-fold increase in full-year profit Reuters 1 day ago
Popular Searches
TOKYO, May 11 (Reuters) - Takeda Pharmaceutical Co on Tuesday reported a five-fold increase in full-year operating profit versus the previous year, driven by sales of its Entyvio colitis treatment and other mainstay drugs.
Operating profit for Japan s largest drugmaker in the year to end March came in at 509 billion yen ($4.68 billion).
That compares with its own earlier estimate of 434 billion yen and a consensus estimate of 567 billion yen from a Refinitiv poll of 14 analysts.
Takeda is importing Moderna Inc s COVID-19 vaccine into Japan and on Monday said that interim results of clinical trials have been positive.
Takeda FY20 Profit Surges, Revenue Down; Sees Weak Profit, Higher Revenues In FY21
Earnings per share were 241 yen, up 747.3 percent from last year.
Core net profit was 655.5 billion yen or 420 yen per share, up 9 percent from last year.
Operating profit for the year grew 407.2 percent year-on-year to 509.3 billion yen or about $4.6 billion. Core operating profit was 967.9 billion yen or about $8.8 billion, up 0.6 percent from the previous year.
Revenue was 3.20 trillion yen or about $28.9 billion, down 2.8 percent from last year. On an underlying basis, revenue grew 2.2 percent, driven by the growth of Takeda s 14 global brands, up 16 percent year-on-year.
For fiscal 2021 ending March 31, 2022, the company projects net profit of 250 billion yen or 160 yen per share, core earnings per share of 394 yen, operating profit of 488 billion yen, and core operating profit of 930 billion yen, all lower than the previous year.
By Syndicated Content
May 11, 2021 | 4:46 AM
TOKYO (Reuters) – Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc’s COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.
Japan’s biggest drugmaker is handling the imports, and discussions are underway with the government to double shipments to 100 million, Takeda CEO Christophe Weber said.
“Japan is behind. So our goal now is to really support an acceleration of the vaccination,” Weber said in a conference call after the company released full-year earnings results.
The company had reported positive interim results from a domestic trial of the Moderna shot, and Weber said he expected approval to come “very soon”.